ClinicalTrials.gg
CompletedNCT02253797Updated Oct 1, 2014

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

A Phase 1 interventional study of 14C-Tipranavir and Tipranavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

Study to evaluate the pharmacokinetics of Tipranavir and its metabolites including excretion and mass balance of parent compound and radioactivity at steady-state; to isolate, identify and quantify major metabolites of tipranavir in plasma, urine and feces

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy -negative male subjects as determined by results of screening. Healthiness was determined by medical history, laboratory testing and 12-lead
  2. Signed written in accordance with Good Clinical Practice (GCP)
  3. Age >18 and \<=60 years
  4. Subjects within 20% of the normal height: weight range defined by the Metropolitan Life Insurance Company Tables
  5. Ability to swallow numerous large capsules
  6. Willingness to abstain from smoking, ingesting methylxanthine containing drinks or food (coffee, tea, cola, chocolate, etc.), or ingesting alcohol, St. John's Wort, milk thistle, garlic supplements, Seville oranges, and grapefruit or grapefruit juice for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate, and ) deviating from normal and of clinical relevance
  2. History of disease including metabolic, endocrinologic, immunological, hepatic, renal, gastrointestinal, respiratory, cardiovascular, psychiatric or neurological
  3. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator and/or the sponsor
  4. Subjects with a history of drug abuse or alcoholism
  5. Chronic or relevant acute (within 2 weeks of screening) infections
  6. Subjects who have taken prescription medications, over-the-counter drugs, or herbal preparations within 2 weeks of the start of the trial
  7. Participation in another trial with an drug (in the 30 days prior to screening)
  8. Blood donation >400 mL (within 1 month prior to treatment administration or during the trial)
  9. Any laboratory value that represents a Division of DAIDS (DAIDS) toxicity Grade >1
  10. Positive urine drug screen, positive antibody, positive Ribonucleic acid (RNA), or positive surface antigen
  11. History of any familial bleeding disorder
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)

Study arms

  • Experimental
    TPV/r followed by 14C-radiolabeled TPV

    Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir

    Drug: 14C-Tipranavir · Drug: Tipranavir · Drug: Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Radioactive levels of 14C-Tipranavir in plasma and blood

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  2. Radioactive erythrocyte-plasma partition ratio

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  3. Maximum measured concentration of the analyte in plasma (Cmax)

    14C-radiolabeled Tipranavir + Tipranavir

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  4. Plasma concentration 12 hours after dosing (Cp12h)

    14C-radiolabeled Tipranavir + Tipranavir

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  5. Area under plasma concentration time curve (AUC)

    14C-radiolabeled Tipranavir + Tipranavir

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  6. Time of maximum concentration (Tmax)

    14C-radiolabeled Tipranavir + Tipranavir

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  7. Apparent terminal half life (t1/2)

    14C-radiolabeled Tipranavir + Tipranavir

    Time frame: -10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration

  8. Cumulative amount of 14C- radioactivity in Urine and feces

    Time frame: up to 15 days

  9. Percent excretion in urine and feces

    relative to total radioactivity administered

    Time frame: up to 15 days

  10. Time needed to achieve steady-state as determined by tipranavir trough concentrations

    Time frame: up to 15 days

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: up to 15 days

  2. Number of subjects with abnormal changes in laboratory parameters

    Time frame: up to day 14

  3. Number of subjects with clinically significant changes in Electrocardiogram (ECG)

    Time frame: up to day 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003 and a primary completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Oct 1, 2014
Start
Jul 2003
Primary completionActual
Jul 2003
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02253797
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Jul 2003
Primary completion
Jul 2003
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir

Start the discussion